Skip to search.
 TSX Up0.37% TSX Ventures 0.00%

More On I.TO

Quotes

Charts

News & Info

Company

Analyst Coverage

Ownership

  • Major Holders
  • Insider Transactions
  • Insider Roster

Financials


IntelliPharmaCeutics International, Inc. (I.TO)

-Toronto
3.89 Down 0.11(2.75%) Apr 17, 3:58PM EDT
Add to Portfolio
ProfileGet Profile for:
IntelliPharmaCeutics International, Inc.
30 Worcester Road
Toronto, ON M9W 5X2
Canada - Map
Phone: 416-798-3001
Fax: 416-798-3007
Website: http://www.intellipharmaceutics.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Biotechnology
Full Time Employees:38

Business Summary 

Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled and targeted release oral solid dosage drugs in Canada. The company has a pipeline of products based on its patented Hypermatrix technology in various stages of development in therapeutic areas, such as neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. Its products under FDA review include Focalin XR, an extended release capsule for hyperactivity disorders; Effexor XR, an extended release capsule for depression; Protonix, a tablet for gastroesophageal reflux diseases; Glucophage XR, a tablet for managing type 2 diabetes; Seroquel XR, a tablet for the treatment of schizophrenia, bipolar disorders, and depressive disorders; Lamictal XR, a tablet for anti-convulsant for epilepsy; and Keppra XR, a tablet for the treatment of partial onset seizures for epilepsy, as well as Pristiq, a tablet for depression. The company is also developing Coreg CR, a capsule, which is in late-stage development for heart failure and hypertension; OxyContin, a controlled release capsule that is in phase I clinical trial for pain; and Lyrica, a capsule, which is in phase I clinical trial for neuropathic pain. Its non-generic products under development include Rexista, an oral formulation for pain relief; and Regabati XR, a pregabalin extended release capsule that has completed an initial phase I clinical trial for neuropathic pain. The company has a license and commercialization agreement with Par Pharmaceutical, Inc. for the development and commercialization of generic Focalin XR. Intellipharmaceutics International Inc. is headquartered in Toronto, Canada.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on IntelliPharmaCeutics International, Inc.

Key Executives 
 PayExercised
Dr. Isa Odidi Ph.D., MBA, 56
Co-Founder, Chairman, Chairman of Scientific Advisory Board, Chief Exec. Officer and Co-Chief Scientific Officer
521.00k0.00
Dr. Amina Odidi Ph.D., 54
Pres, Chief Operating Officer, Principal Accounting Officer, Co-Chief Scientific Officer and Director
521.00k0.00
Mr. Shameze Rampertab B.Sc. MBA, CA, CPA,
Chief Financial Officer and VP of Fin.
255.00k0.00
Mr. John Newell Allport B.A.Sc., M.A., LL.B., 68
VP of Legal Affairs & Licensing, Sec., Director and Member of Corp. Governance Committee
153.00k0.00
Mr. Glenn Neumann ,
Director of Investor Relations
N/AN/A
Amounts are as of 2013-12-31 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in CAD.